Up and Down: EPlus, Celsion, Human Genome Sciences

*EPlus (PLUS.PK) shares rose 12 percent last week, closing at $10.80. The biggest jump came Tuesday, the day the Herndon firm announced that subsidiary ePlus Technology was recertified as a Microsoft Gold Partner in the United States and earned new Microsoft Gold Competencies. Shares of the technology solutions provider are at the high end of their 52-week range; the low point of the past year came in August, when shares were at $5.50.

*Another big gainer was Jos. A. Bank Clothiers (JOSB) of Hampstead, Md., whose shares gained 10 percent last week to close at $24.40. They gained 16.8 percent on Thursday, when the men's clothing company said that its fiscal year profit rose 16 percent, to a record $50.2 million, and that same-store sales rose 3.8 percent. But then Friday - not a good day for markets overall - shares dropped almost 8 percent.

*Another biotech firm has joined MiddleBrook Pharmaceuticals at the top of the list of three-month gainers: Celsion (CLN) of Columbia. Shares are up 80 percent over that period, closing Friday at $5.25, though they lost 9 percent last week. Celsion got Food and Drug Administration approval in January for trials of its cancer drug ThermoDox.

*Fannie Mae (FNM) of the District and Freddie Mac (FRE) of McLean have been on the movers lists a lot lately, and last week both were on the list of one-week losers. Freddie shares were down 15 percent, closing at $23.40, and Fannie shares were down 14 percent, closing at $26.04.

*Shares of Gladstone Investment (GAIN) of McLean fell 11 percent last week, closing at $8.35. They hit their 52-week low of $8.34 on Friday. On Tuesday, the company named as president David A.R. Dullum, already a director, partner with venture capital firm New England Partners, and president of Harbor Acquisition, and former president George Stelljes III vice chairman. Shares of the investment company have fallen almost 40 percent in the past year.

*Human Genome Sciences (HGSI) has lost 48 percent in the past three months, closing Friday at $6.08. Shares gained about 8 percent on Thursday, the day that Takeda Pharmaceuticals announced its acquisition of Millennium Pharmaceuticals and biotech stocks gained. Humane Genome Sciences shares hit their 52-week high of $11.95 in January and then fell dramatically after the company announced problems with its hepatitis C drug Albuferon, and they haven't rebounded.

By Terri Rupar  |  April 14, 2008; 12:21 PM ET  | Category:  Wall Street
Previous: CapitalSource Buys Calif. Bank | Next: Early Briefing: CircuitBlock CityBuster?


Please email us to report offensive comments.

The comments to this entry are closed.

RSS Feed
Subscribe to The Post

© 2010 The Washington Post Company